IP Library Granted Patent US 7,528,126
Granted Patent B2
US 7,528,126 · App. 10/598,691 · Granted May 5, 2009

Pyrrolobenzodiazepines

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,528,126
App. No.
10/598,691
Granted
May 5, 2009
Kind
B2
Abstract

A compound of formula (I) and salts and solvates thereof, wherein: R 10 is a nitrogen protecting group and R 11 is either OH or O—R 12 , wherein R 12 is an oxygen protecting group, or R 10 and R 11 together form a double bond between N10 and C11; and R 10′ and R 11′ are selected from the same options as R 10 and R 11 respectively.

Claims (15)

1. A compound of formula I:

or a pharmaceutically acceptable salt thereof, wherein:

R 10 and R 11 together form a double bond between N10 and C11 or wherein R 10 is H and R 11 is OH or ORA, RA being C 1-7 alkyl;

and R 10′ and R 11′ are selected from the same options as R 10 and R 11 respectively.

2. A compound of formula I:

wherein:

R 10 is a nitrogen protecting group and R 11 is either OH or O—R 12 , wherein R 12 is an oxygen protecting group;

and R 10′ and R 11′ are selected from the same options as R 10 and R 11 respectively.

3. A compound according to claim 2 , wherein the compounds have the following stereochemistry at the C11 position:

4. A compound according to claim 2 , wherein the nitrogen protecting groups are selected from carbamate nitrogen protecting groups.

5. A compound according to claim 4 , wherein the nitrogen protecting groups are selected from the group consisting of Alloc, Troc, Teoc, BOC, Doc, Hoc, TcBOC, Fmoc, 1-Adoc and 2-Adoc.

6. A compound according to claim 1 , wherein at least 50% is in either the E-, E- or Z-, Z-forms.

7. A pharmaceutical composition comprising a compound of claim 1 or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient.

8. A method for the treatment of an infection, comprising administering to a subject suffering from an infection a therapeutically-effective amount of a compound of claim 1 or a pharmaceutically acceptable salt thereof, wherein the infection is by gram-positive bacteria.

9. The method of claim 8 , wherein the gram-positive bacteria is selected from MRSA and VRE.

Assignments (4)
CORRECTIVE ASSIGNMENT TO CORRECT THE POSTAL CODE OF THE ASSIGNEE PREVIOUSLY RECORDED AT REEL: 036932 FRAME: 0278. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT . Recorded Apr 11, 2017
From: SPIROGEN SÀRL
To: MEDIMMUNE LIMITED
Reel/Frame 042242/0389 →
CONFIRMATORY ASSIGNMENT Recorded Oct 23, 2015
From: SPIROGEN SÀRL
To: MEDIMMUNE LIMITED
Reel/Frame 036932/0278 →
MERGER Recorded May 1, 2013
From: SPIROGEN DEVELOPMENTS SARL
To: SPIROGEN SARL
Reel/Frame 030326/0427 →
CONTRIBUTION AGREEMENT Recorded May 1, 2013
From: SPIROGEN LIMITED
To: SPIROGEN DEVELOPMENTS SARL
Reel/Frame 030326/0454 →